ARTL insider reports two warrants from note conversion and reinvestment

Q: How many shares are covered by the new warrants?

Two warrants cover 9,586 shares at $6.24 and 17,952 shares at $3.40 , each for common stock.

Q: When do the ARTL warrants reported by the CEO expire?

Both warrants reported expire on October 28, 2030 .

Q: What triggered the $6.24 warrant?

A portion of the May 1, 2025 convertible note was automatically converted into the $6.24 warrant on October 28, 2025 .

Q: Which roles does the reporting person hold at ARTL?

He is a Director and an Officer (President, CEO, Treasurer, Secretary).

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Artelo Biosciences (ARTL) insider transaction: President and CEO Gregory D. Gorgas filed a Form 4 reporting October 28, 2025 transactions tied to a previously issued convertible note. A portion of the May 1, 2025 note was automatically converted into a warrant to purchase common stock at $6.24 per share, covering 9,586 shares and expiring on October 28, 2030. In connection with a Subscription Agreement the same day, the remaining portion was converted and reinvested into a new convertible note and a second warrant priced at $3.40 per share for 17,952 shares, also expiring on October 28, 2030. The October Note is convertible into common stock prior to repayment.

Insider Trade Summary

27,538 shares exercised/converted

Mixed 4 txns

Insider Gorgas Gregory D.

Role President, CEO, Treasurer, Sec

Type	Security	Shares	Price	Value
Conversion	Convertible Promissory Note	0	$35,000.00	--
Conversion	Warrant (right to buy)	9,586	$0.00	--
Conversion	Warrant (right to buy)	17,952	$0.00	--
Conversion	Convertible Promissory Note	0	$27,710.00	--

Holdings After Transaction: Convertible Promissory Note — 0 shares (Direct); Warrant (right to buy) — 9,586 shares (Direct)

Footnotes (1)

Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant"). On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

10/30/2025 - 09:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gorgas Gregory D.

(Last)

(First)

(Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, CEO, Treasurer, Sec

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Convertible Promissory Note	⁽¹⁾⁽²⁾	10/28/2025		C⁽¹⁾⁽²⁾			$35,000	05/01/2025	10/28/2025	Common Stock	⁽¹⁾⁽²⁾	$35,000	$0.00	D
Warrant (right to buy)	$6.24	10/28/2025		C⁽¹⁾⁽²⁾		9,586		10/28/2025	10/28/2030	Common Stock	9,586	⁽²⁾⁽¹⁾	9,586	D
Warrant (right to buy)	$3.4	10/28/2025		C⁽¹⁾⁽²⁾		17,952		10/28/2025	10/28/2030	Common Stock	17,952	⁽¹⁾⁽²⁾	17,952	D
Convertible Promissory Note	$3.4	10/28/2025		C⁽¹⁾⁽²⁾		$27,710		10/28/2025	04/28/2026	Common Stock	⁽¹⁾⁽²⁾	$27,710	$27,710	D

Explanation of Responses:

1. Pursuant to the terms of the convertible note issued to the Reporting Person on May 1, 2025 (the "May Note"), on October 28, 2025, a portion of the May Note was automatically converted into a warrant to purchase shares of the Issuer's common stock ("Common Stock") (the "$6.24 Warrant").

2. On October 28, 2025, the Issuer entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which certain investors, including the Reporting Person, converted and reinvested the portion of the May Note not converted into the $6.24 Warrant into (i) a convertible note (the "October Note"), and (ii) a warrant to purchase shares of the Issuer's Common Stock pursuant to the Subscription Agreement (the "$3.40 Warrant"). At any time prior to payment in full of the principal amount of the October Note, the Reporting Person has the right to convert the principal amount of the October Note, together with the accrued and unpaid interest thereon, into shares of the Issuer's Common Stock.

Remarks:

	/s/ Gregory D. Gorgas	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ARTL’s CEO report on Form 4?

Gregory D. Gorgas reported converting portions of a prior convertible note into two warrants and a new convertible note on October 28, 2025.

How many shares are covered by the new warrants?

Two warrants cover 9,586 shares at $6.24 and 17,952 shares at $3.40, each for common stock.

When do the ARTL warrants reported by the CEO expire?

Both warrants reported expire on October 28, 2030.

What is the October Note mentioned in the filing?

It is a new convertible note from the Subscription Agreement; the holder may convert principal and accrued interest into common stock before repayment.

What triggered the $6.24 warrant?

A portion of the May 1, 2025 convertible note was automatically converted into the $6.24 warrant on October 28, 2025.

Which roles does the reporting person hold at ARTL?

He is a Director and an Officer (President, CEO, Treasurer, Secretary).